Manufacturers across industries are balancing new opportunities with growing complexity as technology, market demand and evolving regulations reshape production. This month’s headlines highlight how robotics and AI are changing the factory floor, why food manufacturers are rethinking ingredients and inspection processes, how U.S. manufacturing growth is creating opportunities for plastics, and why pharmaceutical companies are bringing manufacturing partners into the development process earlier. Together, these stories point to an industry focused on becoming more automated, adaptable and prepared for what comes next.
Intel report shows gap between robotics expectations and readiness
Robotics adoption is accelerating across manufacturing, but many companies may not be prepared for what comes next. According to an Intel-commissioned survey of 800 business and technology leaders, 70% of senior manufacturing leaders expect their organizations to manage a fleet of robots within the next five years, yet only about four in 10 have a formal strategy for managing a combined human and robotic workforce.
As advances in AI, edge computing and real-time software make robots more intelligent and adaptable, manufacturers are moving beyond machines that perform fixed, repetitive tasks. However, the report identified a 26% preparedness gap in manufacturing, with challenges ranging from workforce training and safety to unclear ownership of robotics strategy and the ability to scale deployments. Manufacturers that address these operational and workforce issues now may be better positioned to move robotics beyond pilot programs and successfully integrate the technology throughout their operations.
Food Makers Navigate Challenges in Natural Colors Shift
Food and beverage manufacturers are accelerating efforts to replace petroleum-based synthetic dyes with natural alternatives as federal guidance and changing consumer preferences put pressure on the industry. Major companies are already making changes: Nestlé USA removed artificial colors from its U.S. food and beverage portfolio, while Mars Wrigley is working to introduce naturally colored versions of products such as M&M’s, Skittles and Starburst.
But reformulation is far more complicated than swapping one ingredient for another. Natural colors such as spirulina can be more expensive, sensitive to temperature and pH, and difficult to source at the scale large manufacturers require. Manufacturers may also need to adjust processing conditions, packaging and supply chains to maintain product consistency. With federal guidance encouraging a transition away from petroleum-based colors by the end of 2026, manufacturers are balancing regulatory expectations with cost, performance, availability and consumer acceptance.
US Manufacturing Growth Signals Opportunity for Plastics Industry
U.S. manufacturing continued to show positive momentum in 2026, creating potential opportunities for the plastics industry. According to Plastics Industry Association Chief Economist Perc Pineda, the Industrial Production Index recorded six consecutive months of gains through July, with manufacturing output increasing 1.3% year over year. New orders also climbed 1.6% from May to June and were up 7.4% compared with the previous year.
However, the recovery isn't occurring evenly across manufacturing. Much of the growth is concentrated in transportation equipment, defense and AI-related technology supply chains—all sectors that rely heavily on plastics. For plastics manufacturers, continued growth in these markets could translate into stronger demand, but long-term momentum will depend on investment, capacity expansion and the industry's ability to remain globally competitive.
Why peptide developers are turning to CDMOs earlier in the development process
As demand for peptide-based drugs grows, pharmaceutical companies are increasingly turning to contract development and manufacturing organizations (CDMOs) earlier in the development process. The popularity of GLP-1 therapies and continued investment in specialized peptide treatments have contributed to shortages in both manufacturing capacity and technical expertise. As a result, CDMOs are evolving from traditional manufacturing providers into strategic partners that help with process design, optimization, impurity control and regulatory preparation.
Scaling peptide production also presents significant manufacturing challenges. Processes that work successfully at the laboratory level can behave very differently at commercial scale, particularly as peptide chains become longer and more complex. Batch variability, raw material availability, purification and quality control can all affect production. Bringing CDMOs into the process earlier gives pharmaceutical companies an opportunity to identify these issues before reaching commercial production, potentially reducing delays and improving scalability as demand continues to rise.
AI product inspection turns detection into prevention
Artificial intelligence and machine learning are transforming product inspection on food production lines. Traditionally, metal detectors, X-ray systems and vision technology served primarily as a final checkpoint for contaminants or defective products. Today, these systems can collect and analyze production data in real time, helping manufacturers identify patterns that could signal equipment problems, quality issues or potential failures before they become more serious.
AI-powered vision systems are also improving manufacturers’ ability to detect contaminants that traditional technologies can miss, including plastic film, rubber fragments and pieces of protective equipment. When data from vision systems, X-rays, metal detectors and checkweighers is combined, AI can spot abnormalities that might not trigger any individual inspection system. Along with stronger traceability and automated recordkeeping, these capabilities are shifting food inspection from a reactive quality-control measure toward a more proactive approach to food safety, maintenance and production efficiency.
